Vertex Pharmaceuticals has solid revenue projections for its CF franchise, and a promising drug pipeline, especially in pain.

GV20 Therapeutics (GV20), a clinical-stage AI-powered biotherapeutics company, today announced that Dr. Kristopher Wentzel ...

The company expects revenue to grow in the mid to high single digits in FY26 but has not offered specific margin guidance for the year.

The company projects revenue growth of mid- to high single digits in FY26 compared with an 8.5% increase in FY25 ...